Research programme: p38 MAP kinase inhibitors - NovartisAlternative Names: p38 MAP kinase inhibitors research programme - Novartis
Latest Information Update: 14 Jul 2010
At a glance
- Originator Novartis
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 14 Jul 2010 Discontinued - Preclinical for Inflammation in Europe (unspecified route)
- 09 Dec 2004 Preclinical trials in Inflammation in Europe (unspecified route)